MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim

Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity

(2013) D Min et al.   BRITISH JOURNAL OF CANCER

MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma

(2013) Shibo Lin et al.   Cancer Cell International

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

(2013) F. Catalanotti et al.   CLINICAL CANCER RESEARCH

Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions

(2013) M. Courcelles et al.   Molecular Systems Biology

Long Noncoding RNA HOTAIR Is a Prognostic Marker for Esophageal Squamous Cell Carcinoma Progression and Survival

(2013) Xiao-Bin Lv et al.   PLoS One

Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer

(2013) Guang-Hui Liu et al.   TUMOR BIOLOGY

The Role of microRNAs in the Tumorigenesis of Ovarian Cancer

(2013) Gianpiero Di Leva et al.   Frontiers in Oncology

MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene

(2012) Xia Liu et al.   CELL CYCLE

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

(2012) G. Migliardi et al.   CLINICAL CANCER RESEARCH

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma

(2012) Sapna P Patel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

(2012) E. Martin-Sanchez et al.   HAEMATOLOGICA

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines

(2012) Brigette B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor

(2012) Takumi Kawabata et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

ERK1/2 MAP kinases: Structure, function, and regulation

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation

(2012) G. Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

(2011) Bjoern Chapuy et al.   BRITISH JOURNAL OF HAEMATOLOGY

CCL11-CCR3 Interactions Promote Survival of Anaplastic Large Cell Lymphoma Cells via ERK1/2 Activation

(2011) T. Miyagaki et al.   CANCER RESEARCH

miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer

(2011) Akihiko Tsuchida et al.   CANCER SCIENCE

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

(2011) K. M. Kinross et al.   MOLECULAR CANCER THERAPEUTICS

miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro

(2011) Xiao-Bin Lv et al.   Chinese Journal of Cancer

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

(2010) Yohannes Mebratu et al.   CELL CYCLE

MAP Kinase-Mediated c-fos Regulation Relies on a Histone Acetylation Relay Switch

(2008) Amanda O'Donnell et al.   MOLECULAR CELL

Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

(2008) J A Wickenden et al.   ONCOGENE